Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 7/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590310 | 0.79 | TTR (0.57) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL1447228 | 0.77 | TTR (0.56) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL3588102 | 0.77 | TTR (0.69) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL3580412 | 0.77 | TTR (0.55) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL3589380 | 0.77 | TTR (0.55) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL3584612 | 0.76 | TTR (0.57) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL7370239 | 0.76 | TTR (0.72) | TTRLMNAGPR35MEN1ALDH1A1 | |
| SCHEMBL3581513 | 0.76 | FTO (0.57) | LMNAGPR35MEN1ALDH1A1MAPT | |
| SCHEMBL3581518 | 0.76 | FTO (0.57) | LMNAGPR35MEN1ALDH1A1MAPT | |
| SCHEMBL27656222 | 0.75 | LMNA (0.56) | LMNACYP2C9RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9446012-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-09-20 | — | — | US | disclosed |
| CN-102816157-B | As the Nitrocatechol derivatives of COMT inhibitor | BIAL - PORTELA & CA., S.A. (PT) | 2016-05-18 | — | — | CN | disclosed |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2014-01-23 | — | — | US | disclosed |
| US-8536203-B2 | Pharmaceutical compounds | BIAL-PORTELA & CA, S.A. (PT) | 2013-09-17 | — | — | US | disclosed |
| EP-2617713-A1 | New Pharmaceutical Compounds | BIAL - Portela & Ca., S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| US-20100168113-A1 | Pharmaceutical Compounds | BIAL-PORTELA & CA., S.A. (PT) | 2010-07-01 | — | — | US | disclosed |
| EP-2027091-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - Portela & Ca., S.A. (PT) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007117165-A1 | NEW PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168113-A1 | Pharmaceutical Compounds | PMP22, CNR2, OPRL1 | TTR 2094/4885LMNA 2903/4885GPR35 428/4885 |
| US-20140024682-A1 | PHARMACEUTICAL COMPOUNDS | PMP22, CNR2, OPRL1 | TTR 2094/4885LMNA 2903/4885GPR35 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.